Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor’s lead investigational candidate, ENV-101, is an inhibitor of the Hedgehog (Hh) signaling pathway in clinical development for the treatment of fibrotic lung disease, including idiopathic pulmonary fibrosis (IPF). The company’s second investigational candidate, ENV-501 is a human epidermal growth factor 3 (HER3)-targeted antibody-drug conjugate (ADC) for the treatment of HER3-positive solid tumors.
OUR SCIENCE
Our approach is embodied in our pipeline of potential therapies that precisely target the root cause of disease to deliver transformational clinical benefits and the potential to change treatment expectations.
Our leadership team has deep experience developing drug candidates into leading medicines that make a meaningful difference in patients’ lives.
OUR LEADERSHIP
OUR CULTURE
We have a vibrant and passionate culture that reflects our shared mission to deliver new therapeutic options for patients with life-threatening diseases.
LATEST NEWS
Endeavor BioMedicines Appoints Bill Bradford, M.D., Ph.D., to Board of Directors
SAN DIEGO – September 12, 2024 – Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the appointment of Williamson “Bill” Bradford, M.D., Ph.D., to the company’s board of directors. Dr. Bradford brings over two...
New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines’ ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis
Data presented for the first time today during late-breaking oral session at the American Thoracic Society 2024 International Conference Patients who received ENV-101 experienced statistically significant improvements in lung function and total lung capacity, and reversal of multiple key quantitative measures of lung fibrosis through 12 weeks of treatment Findings reinforce potential...
Endeavor BioMedicines to Present New Data From Phase 2a Clinical Trial of ENV-101 at American Thoracic Society 2024 International Conference
Data from Phase 2a trial of novel Hedgehog (Hh) signaling pathway inhibitor in patients with idiopathic pulmonary fibrosis selected for featured late-breaking oral presentation on May 19 SAN DIEGO – May 1, 2024 – Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical...
Fibrotic Lung Disease
ENV-101 has the potential to be the first-ever disease-modifying therapy for pulmonary fibrosis, including IPF.
Oncology
ENV-501 is an optimized next-generation anti-HER3 antibody-drug conjugate with the potential to treat multiple tumor types.